The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors - A comparative study with inhibin B

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1661-1671

  Färkkilä, Anniina ^a   Koskela, Sanna ^b   Bryk, Saara ^a   Alfthan, Henrik ^a   Bützow, Ralf ^a   Leminen, Arto ^a   Puistola, Ulla ^b   Tapanainen, Juha S ^a,b   Heikinheimo, Markku ^a,c   Anttonen, Mikko ^a   Unkila Kallio, Leila ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

anti M llerian hormone; granulosa cell tumor; inhibin B; ovarian cancer; serum marker

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBIN B; MUELLERIAN INHIBITING FACTOR; INHIBIN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; FEMALE; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VERY ELDERLY; BLOOD; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; OVARY TUMOR; YOUNG ADULT;

ADULT; AGED; ANTI-MULLERIAN HORMONE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRANULOSA CELL TUMOR; HUMANS; INHIBINS; LONGITUDINAL STUDIES; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84943382102     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29532     Document Type: Article

References (40)

1. Jamieson S, Fuller PJ,. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev 2012; 33: 109-44.
2. Jamieson S, Butzow R, Andersson N, et al., The foxl2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 2010; 23: 1477-85.
3. Shah SP, Kobel M, Senz J, et al., Mutation of foxl2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360: 2719-29.
4. Farkkila A, Andersson N, Butzow R, et al., HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med 2014; 3: 526-36.
5. East N, Alobaid A, Goffin F, et al., Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 2005; 27: 363.
6. Fox H, Agrawal K, Langley FA,. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 1975; 35: 231-41.
7. Cronje HS, Niemand I, Bam RH, et al., Review of the granulosa-theca cell tumors from the Emil Novak ovarian tumor registry. Am J Obstet Gynecol 1999; 180: 323-7.
8. Geerts I, Vergote I, Neven P, et al., The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer 2009; 19: 847-55.
9. Groome NP, Illingworth PJ, O'Brien M, et al., Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996; 81: 1401-5.
10. Petraglia F, Luisi S, Pautier P, et al., Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 1998; 83: 1029-32.
11. Robertson DM, Cahir N, Burger HG, et al., Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol (Oxf) 1999; 50: 381-6.
12. Mom CH, Engelen MJ, Willemse PH, et al., Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 2007; 105: 365-72.
13. Nelson SM,. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013; 99: 963-9.
14. Weenen C, Laven JS, Von Bergh AR, et al., Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77-83.
15. van Rooij IA, Broekmans FJ, Scheffer GJ, et al., Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005; 83: 979-87.
16. Piltonen T, Morin- PL, Koivunen R, et al., Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20: 1820-6.
17. Hehenkamp WJ, Looman CW, Themmen AP, et al., Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006; 91: 4057-63.
18. Rey R, Sabourin JC, Venara M, et al., Anti-Mullerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000; 31: 1202-8.
19. Anttonen M, Farkkila A, Tauriala H, et al., Anti-Mullerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. Lab Invest 2011; 91: 1605-14.
20. Chang HL, Pahlavan N, Halpern EF, et al., Serum Mullerian inhibiting substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009; 114: 57-60.
21. Gustafson ML, Lee MM, Scully RE, et al., Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992; 326: 466-71.
22. Lane AH, Lee MM, Fuller AF, Jr, et al., Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999; 73: 51-5.
23. Long WQ, Ranchin V, Pautier P, et al., Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000; 85: 540-4.
24. Dorgan JF, Spittle CS, Egleston BL, et al., Assay reproducibility and within-person variation of Mullerian inhibiting substance. Fertil Steril 2010; 94: 301-4.
25. Sowers MR, Eyvazzadeh AD, McConnell D, et al., Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93: 3478-83.
26. Kumar A, Kalra B, Patel A, et al., Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 2010; 362: 51-9.
27. Croghan CW, Egeghy PP., Methods of dealing with values below the limit of detection using SAS. U.S. Environmental Protection Agency, 2003. http://analytics.ncsu.edu/sesug/2003/SD08-Croghan.pdf.
28. Kalra B, Kumar A, Patel K, et al., Development of a second generation inhibin B ELISA. J Immunol Methods 2010; 362: 22-31.
29. Sehested A, Juul AA, Andersson AM, et al., Serum inhibin a and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. J Clin Endocrinol Metab 2000; 85: 1634-40.
30. Rustin GJ, Nelstrop AE, Tuxen MK, et al., Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames ovary group study. Ann Oncol 1996; 7: 361-4.
31. Griesinger G, Dafopoulos K, Buendgen N, et al., Elimination half-life of anti-Mullerian hormone. J Clin Endocrinol Metab 2012; 97: 2160-3.
32. Lappohn RE, Burger HG, Bouma J, et al., Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989; 321: 790-3.
33. Rustin GJ, van der Burg ME, Griffin CL, et al., Early versus delayed treatment of relapsed ovarian cancer (MRC ov05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-63.
34. Fleming ND, Cass I, Walsh CS, et al., Ca125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121: 249-52.
35. Colombo N, Parma G, Zanagnolo V, et al., Management of ovarian stromal cell tumors. J Clin Oncol 2007; 25: 2944-51.
36. di Clemente N, Jamin SP, Lugovskoy A, et al., Processing of anti-Mullerian hormone regulates receptor activation by a mechanism distinct from TGF-{beta}. Mol Endocrinol 2010; 24: 2193-206.
37. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, et al., Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 2006; 12: 1593-8.
38. Rustamov O, Smith A, Roberts SA, et al., Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Hum Reprod 2012; 27: 3085-91.
39. Cappy H, Pigny P, Leroy-Billiard M, et al., Falsely elevated serum antimullerian hormone level in a context of heterophilic interference. Fertil Steril 2013; 99: 1729-32.
40. Iwase A, Sugita A, Hirokawa W, et al., Anti-Mullerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy. Gynecol Endocrinol 2013; 29: 357-60.